CGP 48369
Latest Information Update: 27 Apr 1995
Price :
$50 *
At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 21 Apr 1995 Discontinued-I for Hypertension in Switzerland (Unknown route)